Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

which is marketed in collaboration with Regeneron REGN. This drug is currently a key top-line driver for both SNY and REGN. In 2024, Sanofi recorded more than €13 billion from Dupixent product ...

Aguh, MD, FAAD, is the 2025 recipient of the prestigious Dermatology Foundation-Skin of Color Society Collaborative Mid-Career Award sponsored by Sanofi and Regeneron. Pictured from left ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

PARIS, France I March 20, 2025 I Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

Sanofi—which co-markets the anti-inflammatory blockbuster Dupixent with Regeneron—has been undergoing a major pipeline shake-up in an effort to become “an immunoscience powerhouse ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...

The Dermatology Foundation-Skin of Color Society Collaborative Mid-Career Award sponsored by Sanofi and Regeneron was developed especially for the exceptional mid-career investigator with an ...